Research programme: recombinant protein based therapeutics - TGV Laboratories

Drug Profile

Research programme: recombinant protein based therapeutics - TGV Laboratories

Alternative Names: Rec-D 1

Latest Information Update: 05 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TGV-Laboratories
  • Class Recombinant proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial endocarditis; Graft-versus-host disease; Small cell lung cancer

Most Recent Events

  • 22 Apr 2015 Preclinical trials in Bacterial endocarditis in USA (IV)
  • 10 Dec 2013 Pharmacodynamics data from a preclinical study in Graft versus host disease released by TGV-Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top